High BMI Variability, Adverse Outcomes Linked in Predialysis CKD
Variabilities in metabolic syndrome components linked to prognosis, with worse prognosis for more components with high variability
FRIDAY, Aug. 13, 2021 (HealthDay News) -- For predialysis chronic kidney disease (CKD) patients, those with high body mass index (BMI) variability have an increased risk for adverse outcomes, including mortality, according to a study published online Aug. 12 in the Journal of the American Society of Nephrology.
Sehoon Park, M.D., from the Seoul National University College of Medicine in South Korea, and colleagues conducted a retrospective observational study based on the national health screening database of South Korea to examine the association between BMI or metabolic parameter variability and the prognosis of CKD. Data were included for 84,636 predialysis CKD patients.
The researchers found that higher BMI variability was associated significantly with higher risks for all-cause mortality, kidney replacement therapy, myocardial infarction, and stroke (hazard ratios for highest versus lowest quartile: 1.662, 1.201, 1.191, and 1.189, respectively). In subgroups divided according to positive/negative trends in BMI during the exposure assessment period, the results were similar. Variabilities in certain metabolic syndrome components were significantly associated with the prognosis of predialysis CKD patients; worse prognosis was seen for those with a higher number of metabolic syndrome components with high variability.
"In addition to the assessment of metabolic status at a single time point, health care providers in the field of nephrology should pay attention to recent trends in metabolic parameters in CKD patients, as a higher degree of fluctuation may be associated with future risks of mortality or major adverse outcomes," the authors write.
One author disclosed financial ties to Baxter.